SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives $12.00 Average Target Price from Analysts

Posted by on Jul 22nd, 2026

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $12.00.

Several equities research analysts have recently weighed in on SABS shares. Rodman & Renshaw reissued a “buy” rating and issued a $13.00 price objective on shares of SAB Biotherapeutics in a report on Monday, May 11th. Chardan Capital lifted their target price on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of SAB Biotherapeutics in a research report on Monday, June 15th. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Wednesday, July 8th. Finally, Barclays started coverage on shares of SAB Biotherapeutics in a research report on Wednesday, June 24th. They set an “overweight” rating and a $13.00 price objective on the stock.

View Our Latest Report on SABS

Institutional Investors Weigh In On SAB Biotherapeutics

Several hedge funds have recently made changes to their positions in SABS. Vivo Capital LLC acquired a new position in SAB Biotherapeutics in the 3rd quarter valued at about $22,954,000. Perceptive Advisors LLC lifted its position in SAB Biotherapeutics by 700.8% during the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock worth $24,634,000 after acquiring an additional 5,628,533 shares during the period. RA Capital Management L.P. purchased a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at approximately $8,847,000. Woodline Partners LP purchased a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at approximately $5,730,000. Finally, Spruce Street Capital LP acquired a new position in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $8,222,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Up 3.7%

SABS opened at $3.64 on Friday. SAB Biotherapeutics has a one year low of $1.85 and a one year high of $5.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. The stock has a market capitalization of $278.31 million, a P/E ratio of -1.73 and a beta of 0.52. The business’s 50-day simple moving average is $3.71 and its 200-day simple moving average is $3.85.

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Analysts anticipate that SAB Biotherapeutics will post -1.19 EPS for the current year.

About SAB Biotherapeutics

(Get Free Report)

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.

Featured Stories

Analyst Recommendations for SAB Biotherapeutics (NASDAQ:SABS)

Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.